On the effect of omega-3 supplementation with methylphenidate as an alternative therapy to reduce Attention Deficit Hyperactivity Disorder (ADHD) in children.

Related Articles

On the effect of omega-3 supplementation with methylphenidate as an alternative therapy to reduce Attention Deficit Hyperactivity Disorder (ADHD) in children.

Korean J Pediatr. 2019 May 20;:

Authors: Mohammadzadeh S, Baghi N, Yousefi F, Yousefzamani B

Abstract
Background: Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common behavioral disorders in children and one of the health chronic disorders at school age.
Purpose: This study was conducted to evaluate the effect of omega-3 supplementation as an alternative therapy in children with ADHD, which can be due to vitamins and minerals deficiencies.
Methods: This study was a double-blinded clinical trial study. Sixty six children with ADHD, referring to the child and adolescent psychiatric educational and therapeutic clinic, aged 6 to 12 years were selected based on DSM-IV-TR criteria. For assessment of ADHD, in 0, 2, 4 and 8 weeks, the instruments include Parent ADHD Rating Scale were used.
Results: The results showed that there were no statistically significant difference between the methylphenidate with omega-3 group and methylphenidate with placebo group based on the Parents ADHD Rating Scale for baseline weeks (P≥0.96) and eight weeks (P≥0.75) . In addition, there were no significant difference between the Inattention (P≥0.48) and Hyperactivity/Impulsivity (P≥0.80) subscales in the Parents ADHD Rating Scale in the two groups. The results showed that the most common drug complication of anorexia 27(54%) and diarrhea10(20%) in methylphenidate with placebo group, also, common drug complication of anorexia 41(60.29%) and diarrhea 8(11.76%) in methylphenidate with omega-3 group, but, no significant difference between two groups (P>0.05).
Conclusion: The results of our study showed that a specific dose of omega-3 for eight weeks had no effect on the treatment of ADHD.

PMID: 31122010 [PubMed – as supplied by publisher]

via https://www.ncbi.nlm.nih.gov/pubmed/31122010?dopt=Abstract